Treatments and Trials

Subscribe to Treatments and Trials feed
HealthUnlocked RSS Feed
Updated: 1 hour 56 min ago

Ibrutinib and Obinutuzumab with Venetoclax

17 February 2019
Hello, I am new here. My husband needs to start first time treatment for CLL as soon as possible. He was given info. about the clinical trial which adds Venetoclax to Ibrutinib and Obinutuzmab. Half of the participants will receive the Venetoclax. His other option is to be given just the Ibrutinib. We do not know how to make this decision. Since he usually gets side effects to every drug he takes, he is leaning strongly towards just taking the one drug. His oncologist has not really discussed...

US Government Approval for Funding of CAR-T therapy

17 February 2019
Hi,
CMS approves CAR-T therapy payment, but with significant strings attached. For more details see: cllsociety.org/2019/02/cms-...
This is a positive first step, but only the first step. We will be interviewing experts on funding over the next few weeks .
I am proud of the small role I played in this by going to CMS and lobbying on behalf of future CAR-T patients.
Stay strong.
We are all in this together.
Brian
Brian Koffman MDCM DCFP, DABFM, MS Ed ...

"Whole bacterial" pneumonia vaccine approaches human trials

08 February 2019
"Professor James Paton, a director at GPN Vaccines and Director of the University of Adelaide's Research Centre for Infectious Diseases, says that the current pneumococcal vaccine works by targeting the complex carbohydrates that coat the outside of the Streptococcus pneumoniae bacterium, which is the main cause of pneumonia. He points out that this vaccine, which costs more than US$100 a shot, only covers 13 types of these complex carbohydrates, when there are 98 structurally distinct types....

Ibrutinib plus CD19-specific CAR T-cell therapy may benefit patients with relapsed or refractory CLL

03 December 2018
Administration of ibrutinib beginning 2 weeks prior to leukapheresis and continuing until 3 months after CD19-specific chimeric antigen receptor T-cell therapy appeared well tolerated among patients with relapsed or refractory chronic lymphocytic leukemia, according to retrospective study results presented at ASH Annual Meeting and Exposition. ...

Summary of UK CLL Trials Portfolio ~ November 2018

18 November 2018
The summary of current CLL trials has been updated and is available by following the link below
www.cllsupport.org.uk/artic...